So, as we’ve discussed over the past few days (check yesterday’s blog, if you want), the FDA approved Aduhelm, the monoclonal antibody that attaches to amyloid. The problem is that there is no clinical data demonstrating this will help alleviate the memory loss in Alzheimer’s patients- despite the FDA approval.
Continue reading Alzheimers- but not Aduhelm
Share this:
